CCNA2, CCNB1, CDK1, CKS2, DLGAP5, and MAD2L1 are correlated with the pathological CRC stage which means that they may be useful as new independent prognostic biomarkers in predicting the clinical treatment effect in CRC patients. This evidence concerns the gene DLGAP5 and colorectal carcinoma.